Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call

Rhea-AI Summary

Medexus Pharmaceuticals (MEDXF) has scheduled its Q4 and fiscal year 2025 earnings conference call for June 26, 2025, at 8:00 am Eastern Time. The company will release its financial statements and MD&A for the period ended March 31, 2025, after market close on June 25, 2025. Investors can join via phone using toll-free number 888-506-0062 (US/Canada) or +1 973-528-0011 (international) with access code 266173. A live webcast will be available on Medexus's Investors website section. A replay will be accessible until July 3, 2025, via phone and until June 26, 2026, via webcast.

News Market Reaction – MEDXF

-0.91%

1 alert

-0.91% News Effect

On the day this news was published, MEDXF declined 0.91%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26, 2025 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2025.

To participate in the call, please dial the following numbers:

888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for international callers

Access code: 266173

A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:

https://www.webcaster4.com/Webcast/Page/2010/52642

A replay of the call will be available approximately one hour following the end of the call through Thursday, July 3, 2025. To access the replay, please dial the following numbers –

877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers

Conference ID: 52642

A replay of the webcast will be available on the Investors section of Medexus's corporate website until Friday, June 26, 2026.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.

Contacts

Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com

Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com

Forward-looking statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255789

FAQ

When is Medexus Pharmaceuticals (MEDXF) Q4 2025 earnings call?

Medexus Pharmaceuticals' Q4 2025 earnings call is scheduled for Thursday, June 26, 2025, at 8:00 am Eastern Time.

What is the dial-in number for MEDXF's Q4 2025 earnings call?

The toll-free dial-in number is 888-506-0062 for US/Canada callers and +1 973-528-0011 for international callers, with access code 266173.

When will Medexus release its Q4 2025 financial results?

Medexus will release its Q4 and fiscal year 2025 financial statements and MD&A after markets close on June 25, 2025.

How long will the replay of MEDXF's Q4 2025 earnings call be available?

The phone replay will be available until July 3, 2025, while the webcast replay will be accessible until June 26, 2026.